RDPAC药品推广行为准则 - IFPMA

研
制
开
发
制
药
企
业
协
会
12
药品研制和开发行业委员会及
其会员公司致力于从事各种造福
患者的教育和推广活动,以及旨
在提高药品使用水平的推广及合
作项目。药品研制和开发行业委
员会同时致力于维护医疗卫生专
业人士开具处方时的独立性。制
药行业有义务并有责任向医疗卫
生专业人士提供有关自己产品的
准确信息和培训,以使人们对处
方药的正确使用有一个清楚的认
识。制药行业与医疗卫生专业人
士之间的任何联系均须有助于医
疗卫生专业人士履行其对患者所
负有的职业道德义务,并与该义
务保持协调一致。制药公司在进
行产品的推广活动时应保持高水
平的道德标准,并应遵守现行的
法律、法规及相关的执业要求。
本准则完全依照中国相关法
律法规 1 、为向医疗卫生专业人士
进行符合道德规范的药品推广制
订了一系列准则,并帮助确保会
员公司与医药卫生专业人士及其
他利益相关人士的互动交流是适
当的并受到公众的认可。
RDPAC and its Members are committed
to educational and promotional
efforts that benefit patients and promotional
programs and collaborations
that enhance the practice of medicine.
RDPAC also seeks to preserve
the independence of the decisions
taken by healthcare professionals in
prescribing pharmaceutical products
to patients. The pharmaceutical industry
has an obligation and responsibility
to provide accurate information
and education about its products
to healthcare professionals in order
to establish a clear understanding of
the appropriate use of prescription
pharmaceutical products. Industry
relationships with healthcare professionals
must support, and be consistent
with, the professional responsibilities
healthcare professionals have
towards their patients. Pharmaceutical
companies must maintain high
ethical standards when conducting
promotional activities and comply
with applicable legal, regulatory and
professional requirements.
The RDPAC Code sets forth standards
for the ethical promotion of
pharmaceutical products to healthcare
professionals and helps ensure
that member companies’ interactions
with healthcare professionals and
other stakeholders are appropriate
and perceived as such, while in full
compliance with the relevant Chinese
laws and regulations 1 .